Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis

被引:239
作者
McMahon, GA
Petitclerc, E
Stefansson, S
Smith, E
Wong, MKK
Westrick, RJ
Ginsburg, D
Brooks, PC
Lawrence, DA
机构
[1] Amer Red Cross, Dept Vasc Biol, Holland Lab, Rockville, MD 20855 USA
[2] Univ Laval, Ctr Rech, Hotel Dieu, Quebec City, PQ G1R 2J6, Canada
[3] Univ Pittsburgh, Pittsburgh Canc Inst, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA
[4] Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Med Ctr, Dept Human Genet, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA
[7] NYU, Sch Med, Kaplan Canc Ctr, Dept Radiat Oncol, New York, NY 10016 USA
[8] NYU, Sch Med, Kaplan Canc Ctr, Dept Cell Biol, New York, NY 10016 USA
关键词
D O I
10.1074/jbc.M105980200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Elevated expression of plasminogen activator inhibitor-1 (PAI-1) in tumors is associated with a poor prognosis in many cancers. Reduced tumor growth and angiogenesis have also been reported in mice deficient in PAI-1. These results suggest that PAI-1 may be required for efficient angiogenesis and tumor growth. In the present study, we demonstrate that PAI-1 can both enhance and inhibit the growth of M21 human melanoma tumors in nude mice and that this appears to be due to PAI-1 regulation of angiogenesis. Quantitative analysis of angiogenesis in a Matrigel implant assay indicated that in PAI-1 null mice angiogenesis was reduced similar to 60% compared with wild-type mice, while in mice overexpressing PAI-1, angiogenesis was increased nearly 3-fold. Furthermore, addition of PAI-1 to implants in wild-type mice enhanced angiogenesis up to 3-fold at low concentrations but inhibited angiogenesis nearly completely at high concentrations. Together, these data demonstrate that PAI-1 is a potent regulator of angiogenesis and hence of tumor growth and suggest that understanding the mechanism of this activity may lead to the development of important new therapeutic agents for controlling pathologic angiogenesis.
引用
收藏
页码:33964 / 33968
页数:5
相关论文
共 36 条
[1]   The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin:: Implications for antiangiogenic strategies [J].
Bajou, K ;
Masson, V ;
Gerard, RD ;
Schmitt, PM ;
Albert, V ;
Praus, M ;
Lund, LR ;
Frandsen, TL ;
Brunner, N ;
Dano, K ;
Fusenig, NE ;
Weidle, U ;
Carmeliet, G ;
Loskutoff, D ;
Collen, D ;
Carmeliet, P ;
Foidart, JM ;
Noël, AS .
JOURNAL OF CELL BIOLOGY, 2001, 152 (04) :777-784
[2]   Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization [J].
Bajou, K ;
Noël, A ;
Gerard, RD ;
Masson, V ;
Brunner, N ;
Holst-Hansen, C ;
Skobe, M ;
Fusenig, NE ;
Carmeliet, P ;
Collen, D ;
Foidart, JM .
NATURE MEDICINE, 1998, 4 (08) :923-928
[3]   MOLECULAR EVOLUTION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 FUNCTIONAL STABILITY [J].
BERKENPAS, MB ;
LAWRENCE, DA ;
GINSBURG, D .
EMBO JOURNAL, 1995, 14 (13) :2969-2977
[4]   PHYSIOLOGICAL CONSEQUENCES OF LOSS OF PLASMINOGEN-ACTIVATOR GENE-FUNCTION IN MICE [J].
CARMELIET, P ;
SCHOONJANS, L ;
KIECKENS, L ;
REAM, B ;
DEGEN, J ;
BRONSON, R ;
DEVOS, R ;
VANDENOORD, JJ ;
COLLEN, D ;
MULLIGAN, RC .
NATURE, 1994, 368 (6470) :419-424
[5]   PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENE DEFICIENT MICE .1. GENERATION BY HOMOLOGOUS RECOMBINATION AND CHARACTERIZATION [J].
CARMELIET, P ;
KIECKENS, L ;
SCHOONJANS, L ;
REAM, B ;
VANNUFFELEN, A ;
PRENDERGAST, G ;
COLE, M ;
BRONSON, R ;
COLLEN, D ;
MULLIGAN, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2746-2755
[6]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[7]   Pigment epithelium-derived factor: A potent inhibitor of angiogenesis [J].
Dawson, DW ;
Volpert, OV ;
Gillis, P ;
Crawford, SE ;
Xu, HJ ;
Benedict, W ;
Bouck, NP .
SCIENCE, 1999, 285 (5425) :245-248
[8]   Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin [J].
Deng, G ;
Royle, G ;
Wang, S ;
Crain, K ;
Loskutoff, DJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (22) :12716-12723
[9]  
Eitzman DT, 1996, BLOOD, V87, P4718
[10]   BRIEF REPORT - COMPLETE DEFICIENCY OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 DUE TO A FRAME-SHIFT MUTATION [J].
FAY, WP ;
SHAPIRO, AD ;
SHIH, JL ;
SCHLEEF, RR ;
GINSBURG, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (24) :1729-1733